Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07149857 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
A Phase 2 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 15
- Study locations
NCT07149857: Recruiting Phase 2 study of Multiple Myeloma, sponsored by Janssen Research & Development.
NCT07149857 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 60 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 15 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07149857, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.
Primary Outcome
Participants in CR or better who achieve MRD-negative status at 12 months after cilta-cel infusion with a sensitivity of 10\^-5, prior to progressive disease (PD) or subsequent anti-myeloma therapy will be reported.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Cilta-cel
- DRUG Induction therapy
Study Locations (15)
Other
- Royal Prince Alfred Hospital - Camperdown
- Austin Hospital - Heidelberg
- Fiona Stanley Hospital - Murdoch
- Princess Alexandra Hospital - Woolloongabba
- Hosp. Univ. Germans Trias I Pujol - Badalona
- Hosp Univ Vall D Hebron - Barcelona
- Hosp. Clinic de Barcelona - Barcelona
- Hosp. Univ. 12 de Octubre - Madrid
- Clinica Univ. de Navarra - Pamplona
- Hosp Clinico Univ de Salamanca - Salamanca
- Hosp. Univ. Marques de Valdecilla - Santander
- Hosp. Virgen Del Rocio - Seville
Florida
- Moffitt Cancer Center - Tampa
Iowa
- University of Iowa Hospital and Clinics - Iowa City
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2029-04-06 |
| Phase | Phase 2 |
What NCT07149857 shows while recruiting
NCT07149857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT07149857 lists 15 locations in 4 states (Other, Florida, Iowa).
Frequently Asked Questions
What is clinical trial NCT07149857 about?
NCT07149857 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel". The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta...
What is the current status of trial NCT07149857?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-10-03. Estimated completion is 2029-04-06.
What conditions does trial NCT07149857 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT07149857?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Cilta-cel (DRUG), Induction therapy (DRUG).
Who is sponsoring clinical trial NCT07149857?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07149857 being conducted?
This trial has 15 study locations across Florida, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07149857's enrollment target sits among peer trials
60 228th of 438 higher than 205 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI